Summary We have measured the serum concentration of the acute phase reactant, C-reactive protein (CRP), in 20 patients with histologically proven small cell lung cancer undergoing their first pulse of induction cytotoxic chemotherapy. Baseline CRP concentrations were raised in 16 of 20 patients (median baseline CRP 18.5 mg-1; normal range <Omg I-). CRP levels more than doubled in 11 of 20 patients during induction chemotherapy. This acute phase reaction was seen in seven of the 10 chemosensitive patients, but was not observed in any of the five non-responding patients. Five patients were non-evaluable for chemoresponse. These data indicate that there is a previously undescribed quantifiable acute phase response during chemotherapy for small cell lung cancer which has potential for predicting chemoresponse.
The serum concentration of the acute phase reactant Creactive protein (CRP) is raised in inflammatory reactions and tissue destruction (Cooper & Milford Ward, 1979; Fischer & Gill, 1976; Powell, 1979) and also in malignant disorders (Baruah & Gogoi, 1975; Cooper & Milford Ward, 1979; Cooper & Stone, 1979; Cooper & O'Quigley, 1982; Raynes & Cooper, 1983) . Furthermore, C-reactive protein concentrations have been used to monitor disease activity in both inflammatory (Amos et al., 1977) and malignant diseases (Harshman et al., 1974; Rosenthal & Sullivan, 1979) .
Patients with small cell lung cancer are often responsive to chemotherapy and it is from the group that shows the best initial response that long-term survivors may result. As such it would clearly be useful to be able to predict overall response to treatment at an early stage during treatment. We Analysis was performed by immunonephelometry using the Hyland laser nephelometer (Whicher et al., 1978) . Antisera and standards were obtained from Atlantic Antibodies (Scarborough, Maine). Samples were pre-precipitated with 4% polyethylene glycol 6,000 in phosphate buffer (10mmoll-1, pH 7.0), to reduce background turbidity. The co-efficient of variation for the assay (both intra-and interbatch) was less than 10%.
Results
Baseline CRP concentrations were raised in 16 of 20 patients. Median baseline CRP was 18.5mgl-1 (normal range <l0mg1-1). There was no significant difference in median baseline levels in those patients with limited (19mg1-1) and extensive (18mg1-1) disease.
In 11 of 20 patients CRP levels rose significantly and more than doubled. These changes during chemotherapy are illustrated in Figure 1 , which shows a pattern of rising CRP with a peak at 72 h. Such acute phase changes in CRP were seen in seven of the 10 patients who responded to chemotherapy, and in four of the five non-evaluable patients. These elevated patterns were in contrast to the flat profiles (illustrated in Figure 2 ) which were observed in all five nonresponding patients (P <0.05, x2 test with Yate's correction).
Median baseline CRP and median CRP concentrations at 72 h for each group of patients, sub-divided according to chemoresponse, are shown in Table I Figure 2 Flat CRP profiles were seen in all five patients who did not respond (NR) to chemotherapy. rise from median baseline in the non-responding group of patients.
Discussion
We found serum concentrations of CRP to be raised in patients with small cell lung cancer. This is a finding which is in keeping with published data in other malignant disorders (Baruah & Gogoi, 1975; Cooper & Milford Ward, 1979; Cooper & Stone, 1979; Cooper & O'Quigley, 1982; Raynes & Cooper, 1983) . However, we did not find an association between disease extent and baseline CRP concentrations. This is in contrast to the findings of other researchers who have reported such an association in the case of CRP (Cooper & O'Quigley, 1982) and also other acute phase reactant proteins (Harshman et al., 1974; Rosenthal & Sullivan, 1979) . The reason for this is uncertain but may relate to the relatively good condition of our extensive disease patients, all of whom were suitable for aggressive induction chemotherapy.
An acute tumour lysis syndrome following chemotherapy has previously been described in a number of different malignancies (Cadman et al., 1977; Cohen et al., 1980; Ettinger et al., 1978) including small cell lung cancer (Vogelzang et al., 1983) . This syndrome, characterised by a number of acute biochemical upsets including hyperkalaemia, hypocalcaemia and hyperuricaemia is thought to arise because of chemotherapy induced acute tumour lysis (or necrosis). We hypothesised that the acute tumour necrosis in patients with chemosensitive tumours might induce an acute phase reaction which could be quantified by serial measurement of CRP concentrations. This appears to be the case, with seven out of 10 chemoresponsive patients showing a significant rise in CRP. Interestingly, two of those three chemoresponsive patients who did not show a rise in CRP following chemotherapy had baseline CRP levels within the normal range, perhaps indicating the earlier stage of their tumour. Conversely, in the five chemoresistant patients there was little or no change in CRP concentrations during chemotherapy. Figure 2 illustrates the flat CRP profiles seen in all of the five nonresponding patients, presumably a reflection of the reduced or absent necrosis of the resistant tumour.
Furthermore, it should be noted that two of the three patients who died because of acute myelosuppression showed a pronounced rise in CRP concentration with values quadrupling by 72h. This would also sustain the hypothesis that severe chemotherapy induced tumour necrosis, with associated marrow toxicity results in a marked acute phase reaction at the time of injury and before supervening infection is manifest.
As far as we are aware such a quantifiable acute phase reaction following chemotherapy has not been previously described. One group from Scandinavia (Grutzmeier & Von Schenck, 1986 ) has reported no change in CRP levels during chemotherapy for acute leukaemia. However, these patients did not have solid tumours, sampling was performed less frequently and may have missed the sharp rise in CRP concentrations we have found, and an unusually high upper limit of CRP was accepted as normal (Milroy et al., 1987) .
Although the number of patients in this study is small, there does appear to be evidence of a previously undescribed quantifiable acute phase reaction following chemotherapy in patients with chemoresponsive small cell lung tumours, which is not apparent in resistant patients. If confirmed in larger studies, including other solid tumour types, it might be possible to predict chemoresponse and hence tailor treatment more closely to individual patients needs.
